Biomea Fusion
BMEAClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($16.57M) ($14.40M) ($61.98M) ($9.12M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($4.71M) ($4.20M) ($19.33M) ($3.65M)
Operating Income / (Loss)
($21.28M) ($20.80M) ($83.51M) ($12.77M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
— — — —
Income Tax Provision / (Benefit)
— — $0.00M —
NET INCOME / (NET LOSS)
($20.74M) ($16.41M) ($61.80M) ($12.41M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$56.2M$46.6M$55.8M$44.7M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$56.2M$46.6M$55.8M$44.7M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$8.4M$2.8M$2.2M$1.3M
Total Current Assets
$64.7M$49.4M$58.0M$46.3M
Property, Plant and Equipment, Net
$2.8M$0.2M$0.2M$0.1M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$73.2M$55.2M$58.6M$46.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$8.4M$6.4M$3.2M$4.6M
Accrued Expenses & Clinical Liabilities
$2.8M$2.9M$3.0M$1.0M
Total Current Liabilities
$17.6M$15.6M$11.1M$9.3M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$28.1M$24.0M$17.9M$18.4M
Total Liabilities Block
$45.7M$39.6M$29.0M$27.7M
Total Stockholders' Equity
$27.5M$15.6M$29.6M$18.7M
TOTAL LIABILITIES & EQUITY
$73.2M$55.2M$58.6M$46.4M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
3.68x 3.18x 5.23x 4.98x
R&D Expenditure Flow
$39.5M$53.9M$62.0M$9.1M
Net Income / (Loss)
($20.74M) ($16.41M) ($61.80M) ($12.41M)
Depreciation & Amortization
$0.50M $0.40M $1.41M $0.05M
Stock-Based Compensation
$5.74M $7.68M $9.52M $1.58M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
($1.61M) ($7.25M) ($7.82M) ($0.98M)
Change in Payables & Clinical Accruals
($4.70M) ($6.53M) ($9.70M) $1.38M
Other Operating Source / (Use) Changes
($24.06M) ($34.32M) ($1.99M) ($1.28M)
Net Cash from Operating Activities
($44.88M) ($56.43M) ($70.37M) ($11.67M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
$0.00M $0.00M — —
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
$0.00M $0.00M — $0.55M
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$37.20M $5.03M $4.91M —
Net Cash from Financing Activities
$42.82M $44.79M $67.90M —
NET CONSOLIDATED CHANGE IN CASH
($2.06M) ($11.64M) ($2.47M) ($11.12M)
Clinical Trials Registry
Registry ID
Phase / Asset
Status